EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hyaluronic acid therapy in hip osteoarthritis: differential efficacy in secondary osteoarthritis due to inflammatory rheumatic diseases vs. primary osteoarthritis—a step toward phenotyping osteoarthritis

Orazio De Lucia, Carolina Artusi, Enrico Cumbo, Giorgia Trignani, Manuel Sette, Matteo Ferrito, Miriam Perino, Luca Ingrao, Andrea Amati, Antonella Murgo, Roberto Caporali

Frontiers in Musculoskeletal Disorders · 2025

DOI: 10.3389/fmscd.2025.1668235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Musculoskeletal Disorders, 2025. Verfasst von Orazio De Lucia und 10 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The hip joint is frequently affected by osteoarthritis (OA) and is a leading cause of disability. This study aims to assess the long-term efficacy of ultrasound-guided intra-articular viscosupplementation for pain relief in patients with hip osteoarthritis secondary to rheumatic diseases compared to primary OA.

Methods

This single-center, retrospective, observational cohort study included patients with hip OA who received intra-articular injections of hyaluronic acid (HA) (Hylan G-F 20). Fisher's exact test was applied to evaluate baseline variables, with 95% confidence intervals (CI) calculated for differences in mean outcomes.

Results

A total of 55 patients with primary hip OA (POA) and 16 patients with secondary hip OA (SOA) were included. The mean observation period was 31.3 months (±29.9), with an average of 5 intra-articular injections administered. Both groups showed a positive response to HA injections, with the POA group demonstrating a mean Visual Analog Scale (VAS) pain reduction of 2.97 (95% CI 2.38–3.56), compared to 1.28 (95% CI 0.18–2.37) in the SOA group. At the end of follow-up, pain reduction was less pronounced in the SOA group, which showed higher residual VAS pain scores compared to the POA group ( p = 0.029).

Conclusions

This study highlights that HA injections significantly reduce pain in both primary and secondary hip osteoarthritis. However, patients with primary OA experienced greater pain relief, as evidenced by a more substantial reduction in VAS scores compared to those with secondary OA.

Zitieren

APA

Lucia, O. D., Artusi, C., Cumbo, E., Trignani, G., Sette, M., Ferrito, M., Perino, M., Ingrao, L., Amati, A., Murgo, A., & Caporali, R. (2025). Hyaluronic acid therapy in hip osteoarthritis: differential efficacy in secondary osteoarthritis due to inflammatory rheumatic diseases vs. primary osteoarthritis—a step toward phenotyping osteoarthritis. Frontiers in Musculoskeletal Disorders. https://doi.org/10.3389/fmscd.2025.1668235

Vancouver

Lucia OD, Artusi C, Cumbo E, Trignani G, Sette M, Ferrito M, et al. Hyaluronic acid therapy in hip osteoarthritis: differential efficacy in secondary osteoarthritis due to inflammatory rheumatic diseases vs. primary osteoarthritis—a step toward phenotyping osteoarthritis. Frontiers in Musculoskeletal Disorders. 2025. doi:10.3389/fmscd.2025.1668235

BibTeX
@article{Lucia2025,
  author = {Lucia, Orazio De and Artusi, Carolina and Cumbo, Enrico and Trignani, Giorgia and Sette, Manuel and Ferrito, Matteo and Perino, Miriam and Ingrao, Luca and Amati, Andrea and Murgo, Antonella and Caporali, Roberto},
  title = {Hyaluronic acid therapy in hip osteoarthritis: differential efficacy in secondary osteoarthritis due to inflammatory rheumatic diseases vs. primary osteoarthritis—a step toward phenotyping osteoarthritis},
  journal = {Frontiers in Musculoskeletal Disorders},
  year = {2025},
  doi = {10.3389/fmscd.2025.1668235}
}
Kostenlos starten →